Company Encyclopedia
View More
name
ABVC BioPharma
ABVC.US
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. ABVC BioPharma, Inc.
1.912 T
ABVC.USMarket value -Rank by Market Cap -/-

Financial Score

22/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking147/400
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-49.74%E
    • Profit Margin-636.31%E
    • Gross Margin100.00%A
  • Growth ScoreA
    • Revenue YoY56.52%A
    • Net Profit YoY-11.47%D
    • Total Assets YoY46.42%A
    • Net Assets YoY81.63%A
  • Cash ScoreB
    • Cash Flow Margin-15.72%D
    • OCF YoY56.52%A
  • Operating ScoreE
    • Turnover0.04E
  • Debt ScoreB
    • Gearing Ratio31.56%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    ABVC BioPharma | 8-K: FY2025 Q3 Revenue: USD 1.28 M

    LB filings·
    US
    ABVC
    +7.35%
    LB filings·
    US
    ABVC
    +7.35%

    ABVC BioPharma Acquires Taiwan Land for $11 Million

    ABVC BioPharma Inc. has completed two land acquisitions in Taiwan for approximately $11 million. The investments include $7.67 million for a plant factory in Puli for botanical raw materials and drug research, and $3.3 million for agricultural R&D in Longtan. These acquisitions aim to enhance the company's research and manufacturing capabilities in Asia.

    Reuters·
    US
    ABVC
    +7.35%
    Reuters·
    US
    ABVC
    +7.35%

    ABVC Biopharma Ties Executive Compensation to $1B Market Cap Milestone

    ABVC Biopharma Inc. has introduced a performance incentive plan for its directors and officers, contingent on achieving a $1 billion market cap for 30 consecutive trading days by December 31, 2027. Eligible participants will receive shares equal to 1% of the company's outstanding common stock, with a total award cap of $10 million and individual grants capped at $1 million, pending Board approval.

    Reuters·
    US
    ABVC
    +7.35%
    Reuters·
    US
    ABVC
    +7.35%

    ABVC Biopharma Inc. Issues Correction on Accounting Firm Engagement Status

    ABVC Biopharma Inc. has corrected its Current Report on Form 8-K/A regarding the non-renewal of engagement by WWC, P.C., its independent accounting firm, effective October 10, 2024. WWC has not provided a letter confirming agreement with the original report's statements. The update was signed by CEO Uttam Patil on September 12, 2025.

    Reuters·
    US
    ABVC
    +7.35%
    Reuters·
    US
    ABVC
    +7.35%

    ABVC BioPharma (NASDAQ:ABVC) Issues Quarterly Earnings Results

    ABVC BioPharma (NASDAQ:ABVC) reported its quarterly earnings, posting a loss of ($0.13) per share. The company has a negative return on equity of 29.62% and a net margin of 963.46%. Shares traded up 1.0% to $2.97, with a market cap of $50.44 million. Institutional investors hold 11.38% of the stock, with Geode Capital Management increasing its position by 5.8%. ABVC BioPharma is developing several drugs in clinical trials for various medical conditions.

    Market Beat·
    US
    ABVC
    +7.35%
    Market Beat·
    US
    ABVC
    +7.35%
    © 2025 Longbridge｜Disclaimer